glycine has been researched along with Chromosomal Triplication in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS)." | 9.16 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. ( Groopman, J; Kwak, M; Loeliger, K; Maniar, M; Maric, I; Olnes, MJ; Pfannes, L; Scheinberg, P; Shenoy, A; Sloand, EM; Tian, X; Tucker, Z; Weinstein, B; Wilhelm, F; Yong, AS; Young, NS, 2012) |
| "We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS)." | 5.16 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. ( Groopman, J; Kwak, M; Loeliger, K; Maniar, M; Maric, I; Olnes, MJ; Pfannes, L; Scheinberg, P; Shenoy, A; Sloand, EM; Tian, X; Tucker, Z; Weinstein, B; Wilhelm, F; Yong, AS; Young, NS, 2012) |
| "We analyzed 2502 patients with acute myeloid leukemia at diagnosis for NRAS mutations around the hot spots at codons 12, 13, and 61 and correlated the results to cytomorphology, cytogenetics, other molecular markers, and prognostic relevance of these mutations." | 1.33 | Implications of NRAS mutations in AML: a study of 2502 patients. ( Bacher, U; Haferlach, T; Kern, W; Schnittger, S; Schoch, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olnes, MJ | 1 |
| Shenoy, A | 1 |
| Weinstein, B | 1 |
| Pfannes, L | 1 |
| Loeliger, K | 1 |
| Tucker, Z | 1 |
| Tian, X | 1 |
| Kwak, M | 1 |
| Wilhelm, F | 1 |
| Yong, AS | 1 |
| Maric, I | 1 |
| Maniar, M | 1 |
| Scheinberg, P | 1 |
| Groopman, J | 1 |
| Young, NS | 1 |
| Sloand, EM | 1 |
| Kleschevnikov, AM | 1 |
| Belichenko, PV | 1 |
| Villar, AJ | 1 |
| Epstein, CJ | 1 |
| Malenka, RC | 1 |
| Mobley, WC | 1 |
| Bacher, U | 1 |
| Haferlach, T | 1 |
| Schoch, C | 1 |
| Kern, W | 1 |
| Schnittger, S | 1 |
| Sasaki, H | 1 |
| Matsuda, M | 1 |
| Terasawa, T | 1 |
| Ito, T | 1 |
| Fukushima, Y | 1 |
| Kuroki, Y | 1 |
| Matsuyama, S | 1 |
| Benson, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine[NCT01928537] | Phase 3 | 67 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8[NCT00533416] | Phase 1 | 14 participants (Actual) | Interventional | 2007-09-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for glycine and Chromosomal Triplication
| Article | Year |
|---|---|
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
4 other studies available for glycine and Chromosomal Triplication
| Article | Year |
|---|---|
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cognition Disorders; Crosses, Genetic; Dentate Gyrus; Disease | 2004 |
Implications of NRAS mutations in AML: a study of 2502 patients.
Topics: Amino Acid Substitution; Asparagine; Chromosome Inversion; Codon; Gene Frequency; Genes, ras; Glycin | 2006 |
[Analysis of the relative rates of synthesis of G gamma and A gamma globin chains in the erythropoietic bursts in patients with trisomy 13 syndrome].
Topics: Alanine; Chromosomes, Human, Pair 13; Erythroid Precursor Cells; Female; Fetal Hemoglobin; Globins; | 1989 |
Protein and RNA synthesis in trisomic Down's syndrome leucocytes.
Topics: Acid Phosphatase; Alkaline Phosphatase; Carbon Isotopes; Child; Down Syndrome; Glucosephosphate Dehy | 1967 |